MAIA Biotechnology Inc. (AMEX: MAIA), the clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, completed enrollment for its phase 2 trial for THIO, its lead therapy ...

Developers anticipate releasing full efficacy results from the phase 2 THIO-101 trial later this year. With a data cutoff date of August 1, 2024, 16 patients had a survival follow-up period of more ...

For patients with advanced non-small cell lung cancer who progressed on two or more prior regimens, THIO with Libtayo elicited positive responses. Among patients with advanced non-small cell lung ...

THIO, a first-in-class agent, targets telomeres, inducing cancer cell death and activating immune responses in NSCLC. The THIO-101 trial showed a median overall survival of 16.9 months, surpassing ...

CHICAGO, June 05, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted ...

HOUSTON--(BUSINESS WIRE)--A study conducted at The Wistar Institute in collaboration with The University of Texas Southwestern Medical Center has demonstrated the efficacy of targeting aberrantly ...

MAIA Biotechnology Inc. (NYSE: MAIA), a clinical-stage biopharmaceutical company focused on developing and commercializing targeted immunotherapies for cancer, reported positive interim survival ...

CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...

Maia Biotechnology, Inc. (NYSE American:MAIA), a small-cap biotechnology company with a market capitalization of approximately $51 million, announced Monday that it presented efficacy data from its ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), announced today that the first ...